Gazprom Transgaz Saint Petersburg financing development of COVID-19 drug
News from projects and regions
Gazprom Transgaz Saint Petersburg has provided charitable assistance to the Pasteur Research Institute of Epidemiology and Microbiology to finance a pilot research project named “Development of a peptide-based drug for the prevention and treatment of COVID-19.”
The research institute is actively involved in the fight against the new coronavirus. In early April, the institution set up a new laboratory for PCR diagnostic testing of COVID-19 through its own resources. The laboratory operates around the clock for the benefit of healthcare organizations in St. Petersburg.
Background
Gazprom Transgaz Saint Petersburg, a wholly-owned subsidiary of Gazprom, is engaged in natural gas transmission in nine regions of northwestern Russia, as well as natural gas transit to the CIS and Europe. The company operates over 10,000 kilometers of gas trunklines, transporting more than 137 billion cubic meters of gas every year.
The company’s production capacities are comprised of 32 compressor stations, 192 gas compressor units, and 241 gas distribution stations. Gazprom Transgaz Saint Petersburg has 17 branch companies, including 13 gas pipeline operation centers.
The ISO 14001:2004 environmental management system is in place at Gazprom Transgaz Saint Petersburg. The company is headquartered in St. Petersburg and employs around 7,000 people.